Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well‐controlled Type 2 diabetes

Stewart, Murray; Cirkel, Deborah T.; Furuseth, Kristian; Donaldson, Jill; Biswas, Nandita; Starkie, M.; Phenekos, C.; Hamann, Andreas

doi:10.1111/j.1464-5491.2006.01942.x

Cited by 35 publications

(36 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fourth, no detailed inquiry was made regarding medications for diabetes, hypertension, and hyperlipidemia. Oral hypoglycemic medications such as metformin and rosiglitazone, singly or as combined treatment, resulted in lower CRP levels in subjects with T2D [45]. Similarly antihypertensive medications such as beta blockers decreased overall CRP levels.…”

Section: Discussionmentioning

confidence: 97%

Association Between C-Reactive Protein and Type 2 Diabetes in a Tunisian Population

et al. 2011

View full text Add to dashboard Cite

The aim of this study was to investigate the association of CRP levels with type 2 diabetes (T2D) and its related variables in a sample of the Tunisian population. Our sample included 129 patients with T2D and 187 control subjects. Body mass index (BMI), plasma lipids, glucose, insulin, and CRP concentrations were measured for each participant. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. T2D was defined as a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L, the use of anti-diabetic drugs, or both. Statistical analyses were performed using SPSS 11.5. A significant difference in mean values of BMI, plasma lipids, FPG, insulin, and HOMA-IR was observed between subjects with and without T2D. CRP level was significantly higher in subjects with T2D than those without (p = 0.023), and this result persisted even after adjustment for age, gender, BMI, smoking, and alcohol consumption. In both diabetes statuses, log CRP was significantly associated with FPG, insulin, and HOMA-IR. Subjects with elevated CRP levels (>5 mg/L) had an increased risk of T2D (OR = 2.02, 95% CI 1.18-3.46, p = 0.010) than those whose CRP levels were less or equal to 5 mg/L. Even after adjustment for potentially confounding factors, the risk of T2D was still increased in subjects with elevated CRP levels (OR = 1.91, 95% CI 1.08-3.36, p = 0.025). These results suggest that elevated CRP levels are independently associated with T2D.

show abstract

Section: Discussionmentioning

confidence: 97%

Association Between C-Reactive Protein and Type 2 Diabetes in a Tunisian Population

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In addition, switching previously diet-and glyburide-treated patients to metformin resulted in a 3.8-kg weight loss, whereas patients continuing glyburide monotherapy did not experience any significant weight change (12). Research also indicates that combination treatment with metformin appears to mitigate, to some degree, the weight gain associated with SU and TZD therapy (12,15).…”

Section: Metformin Monotherapy and Combination Therapymentioning

confidence: 92%

“…The weight benefits of metformin monotherapy have been demonstrated in several trials reporting a 0.6-to 2.9-kg weight reduction in treatment-naive patients followed for 6 months to 5 yr; most of this weight loss occurred within the first year (12)(13)(14)(15). Often, this outcome was compared with weight increases in the comparator groups in these trials: rosiglitazone (ϩ4.8 kg), glyburide (ϩ1.6 kg) (13), and pioglitazone (ϩ1.9 kg) (14).…”

Section: Metformin Monotherapy and Combination Therapymentioning

confidence: 96%

Weight Beneficial Treatments for Type 2 Diabetes

Meneghini

Orozco-Beltrán

Khunti

et al. 2011

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

Weight-beneficial agents should be considered in patients, particularly obese patients, who fail to reach glycemic targets on metformin therapy. We propose the following treatment choices based on potential weight benefit and blood glucose increment: long-acting GLP-1 agonists (liraglutide), DPP-4 inhibitors, bile acid sequestrants, amylin analogs, and basal insulin for patients with elevated fasting plasma glucose; and short-acting (exenatide) or long-acting GLP-1 agonists, amylin analogs, DPP-4 inhibitors, acarbose, and bile acid sequestrants for patients with elevated postprandial glucose. The weight-sparing effects of insulin detemir, notably in patients with high body mass index, should also be considered when initiating insulin therapy.

show abstract

“…Biguanides (metformin[7, 8], pheformin[9, 10], buformin[11]) and thiazolidinediones (roziglitazone[12], pioglitazone[13–15], troglitazone[16–19]) are two classes of insulin sensitizers that have sparked controversies over the years. Metformin’s site of action is the liver and it is contra-indicated for patients with impaired liver or kidney function[20].…”

Section: Introductionmentioning

confidence: 99%

“…In 2010, roziglitazone (Avandia) was suspended from the European market for elevated cardiovascular risks. Although type 2 diabetes is the only approved use of thiazolidinediones, these drugs are being investigated for PCOS, non-alcoholic steatohepatitis, psoriasis, autism, ovarian hyperstimulation syndrome and other conditions[12, 13]. …”

Section: Introductionmentioning

confidence: 99%

Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys

Beydoun

Kancherla

Stadtmauer

et al. 2013

Gynecological Endocrinology

View full text Add to dashboard Cite

The purpose of this cross-sectional study based on the 2001–2006 National Health and Nutrition Examination Survey is to examine demographic, socioeconomic, lifestyle and reproductive characteristics that may distinguish users and non-users of insulin sensitizing agents among U.S. diabetic, borderline diabetic and non-diabetic women. Use of insulin-sensitizing agents was evaluated among 19579 (3882 diabetic, 387 borderline diabetic and 15310 non-diabetic) women. Overall, 2% of women in the study sample were users of insulin-sensitizers, including metformin, rosiglitazone and pioglitazone. Multivariate logistic regression models were constructed for predictors of insulin-sensitizer use according to diabetic status. In the overall sample, being younger or diabetic were the only factors associated with an increased odds of using insulin-sensitizing agents, after adjustment of confounders. Among diabetics, use of insulin-sensitizing agents was inversely related to age, but not other factors in the multivariable model. Among borderline and non-diabetics, body mass index (BMI) was the only predictor that remained significantly associated with use of insulin-sensitizing agents after controlling for confounders. In conclusion, the main predictors of insulin-sensitizer use are young age and diabetic status in all women, young age in diabetic women and high BMI in borderline and non-diabetic women.

show abstract

Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well‐controlled Type 2 diabetes

Abstract: RSGMET provided similar short-term glycaemic control to MET with greater improvements in estimates of insulin sensitivity, B-cell function and CRP, with less diarrhoea and low risk of biochemical hypoglycaemia, suggesting that early use of combination therapy may be appropriate.

Cited by 35 publications

References 41 publications

Association Between C-Reactive Protein and Type 2 Diabetes in a Tunisian Population

Association Between C-Reactive Protein and Type 2 Diabetes in a Tunisian Population

Weight Beneficial Treatments for Type 2 Diabetes

Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys

Contact Info

Product

Resources

About